Major malformations in offspring of women with epilepsy.
about
Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control studyThe Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs: A Literature ReviewManagement of epilepsy during pregnancy: an updateAn Update on Maternal Use of Antiepileptic Medications in Pregnancy and Neurodevelopment OutcomesCongenital Anomalies in Children of Mothers Taking Antiepileptic Drugs with and without Periconceptional High Dose Folic Acid Use: A Population-Based Cohort StudyImpact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry.Neural tube defects, folate, and immune modulation.Using current evidence in selecting antiepileptic drugs for use during pregnancy.Antiepileptic drugs in women with epilepsy during pregnancyTeratogenic effects of antiepileptic drugsMajor malformations with valproic acid.Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.In utero antiepileptic drug exposure: fetal death and malformationsPractice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and TechnologyDoes folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?Management of epilepsy during pregnancy.Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect.Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges.Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest?Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment SubcommitThe International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.Reproductive and metabolic disorders in women with epilepsy.Is carbamazepine safe to take during pregnancy?Teratogenicity of sodium valproate.Safety of antiepileptic drugs during pregnancy.Valproic acid in epilepsy : pregnancy-related issues.Anticonvulsants in the treatment of bipolar mania.Management of epilepsy in women of childbearing age: practical recommendations.Role of valproate across the ages. Treatment of epilepsy in adults.Birth defects and epilepsy medication.Oxidative stress is increased in women with epilepsy: Is it a potential mechanism of anti-epileptic drug-induced teratogenesis?Optimizing epilepsy management in teenagers.Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?Currently available antiepileptic drugs.Antiepileptic medication during pregnancy: does fetal genotype affect outcome?Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohortsDo lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?Teratogenicity of antiepileptic medications.Italian consensus conference on epilepsy and pregnancy, labor and puerperium.
P2860
Q24631492-F741AA5B-358F-40F4-BE13-422F03B33EF5Q26741366-C55B3D07-E8F8-4947-B105-3AA4C61A7342Q26752470-55D86645-EE9C-4C7A-B3A0-1AAFA8D10614Q28081205-88058BB4-4417-445A-B1F2-7BA73AA748ACQ28546202-4FBC2D12-35D8-4EE8-B55D-87DF1E3B2E76Q30443028-F8E21CB1-0B9F-40A7-8685-7EA583A545EDQ31046235-DD87514D-9524-4CA2-A79E-56BA58C463A0Q33739571-FBFBEC18-E9BD-4E07-8CA4-9D6653FDD210Q33899323-44BBA457-30A7-4EE1-8F83-839D218CD85CQ33949402-132BBDEF-498B-4AB6-AB0C-A95C147EB773Q34267151-9C163F62-403A-4CF4-A861-C7B35877D2E5Q34517882-EF2CF52F-E0E0-4546-A3AE-0F45502319ECQ34544208-1BC31076-73B9-4886-9C75-FCF8A20AC721Q34555052-942F20AD-A0D4-4401-B457-2942789AC384Q34606995-CEC49E22-CB5D-487A-BED5-9BB31CA7D5E5Q34622148-DF1C1D07-D385-459C-A252-9E268E6A07DCQ34722379-9427AAC4-EEAB-441F-8DAF-D38C46068493Q34761058-968C5604-7B16-488C-94C6-C698212E8368Q34823805-439FCA96-1E82-49FA-9553-D9E4F4D1A4BBQ34905287-D2D3AFA4-5521-4A74-9CFE-671DF92F5B7AQ34985706-09435D8C-6D90-45F6-A58B-491D6AD47ABAQ34998063-7265E6F3-33CD-4957-BE7E-784D74D49AB4Q35161328-5DA2DCFD-9C4B-4046-864C-C2B817B3613FQ35756326-DB132750-E5EE-4FF5-B476-3FEBB9D4146EQ36082034-EBE43186-6EBD-4AD1-8520-9390614775B5Q36235506-F12B276A-CCFC-47C2-98C6-4CEA4649BC6BQ36384705-B43050BC-1C11-419A-9CF5-DBD25033308AQ36407359-8FE81F3C-6F4C-48EA-A870-4224C41F3011Q36476623-66397E99-4A68-4B2E-85D6-BBDB456BA656Q36507535-0EFA07A2-8E9F-4EEA-8A81-CCC1DA1B06A7Q36511300-4E8DEC87-9D45-44A4-82D6-11E93BE25ADEQ36543361-0E31438C-7DF7-4582-87AD-5FEF5E45AD9BQ36561919-47A04CD8-EA45-4673-9DDA-7CC95CC890D3Q36603158-4FBF4B90-3573-444E-9F2C-7B015A3B9960Q36697463-52516E55-D131-47D0-9669-6E96097FADDFQ36863422-2AEB0CCA-27D6-4655-AEE4-C4AA264AF53DQ37138858-D464EC60-30EF-4446-8F0B-2A8F879F22BDQ37186130-8D4E537D-5084-4EAF-8361-6BB014DA9DDAQ37262946-65BC1CBB-FB71-4957-8689-2A4253C9C6C7Q37363241-4F05CF9B-AA04-435C-81D7-C1894111C19B
P2860
Major malformations in offspring of women with epilepsy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Major malformations in offspring of women with epilepsy.
@en
type
label
Major malformations in offspring of women with epilepsy.
@en
prefLabel
Major malformations in offspring of women with epilepsy.
@en
P2093
P1433
P1476
Major malformations in offspring of women with epilepsy.
@en
P2093
Erja Kaaja
Risto Kaaja
Vilho Hiilesmaa
P304
P356
10.1212/01.WNL.0000044157.28073.DC
P407
P577
2003-02-01T00:00:00Z